These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
    Author: Yang JQ, Chen L, Xing TY.
    Journal: Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828.
    Abstract:
    OBJECTIVE: To explore the expression of oncogene C-erbB2 in breast cancer, its relationship to estrogen receptor (ER), progesterone receptor (PR) and PS2 and the prognostic significance. METHODS: The expression of oncogene C-erbB2 in 245 cases with breast cancer was detected with immunohistochemical technique (LsAB). RESULTS: Expression of oncogene C-erbB2 was found in 60% cases of breast cancer. Tumors positive for C-erbB2 were 45.19% and 71.55% in ER positive group and ER negative group respectively, while tumors positive for C-erbB2 were 48.08% and 70.43% in PR positive group and PR negative group respectively. The expression of the C-erbB2 was 23.26% in group of PS2 positive and 50.75% in group of PS2 negative (P < 0.05). No significant association of C-erbB2 expression with age and tumor size was noted(P > 0.05), but its expression in breast cancer was correlated with advanced clinical stage, high histological grade, axillary lymph node involvement (P < 0.05). CONCLUSION: C-erbB2 would be helpful to the evaluation of prognosis and treatment in breast cancer.
    [Abstract] [Full Text] [Related] [New Search]